Helix BioPharma to Present Clinical Trial and NASDAQ Uplisting Plans at Q3 Investor Summit

Helix BioPharma Corp. will present at the Q3 2025 Investor Summit Virtual on September 16, 2025, focusing on key developments including a Phase Ib/Randomized Phase II clinical study of L-DOS47 combined with pembrolizumab for first-line non-small cell lung cancer (NSCLC) treatment and a planned NASDAQ uplisting in Q1 2026. This presentation is significant as it underscores the company's progress in advancing oncology treatments that target hard-to-treat cancers, potentially improving patient outcomes and expanding therapeutic options. The clinical study aims to enhance the effectiveness of existing anti-cancer therapies by priming tumors for increased sensitivity, which could lead to more manageable cancer conditions and better survival rates for NSCLC patients, a common and often aggressive form of lung cancer.

The Investor Summit, an exclusive virtual event for investors specializing in small and microcap stocks, provides a platform for Helix to engage with institutional investors and high-net-worth individuals, offering insights into the company's growth strategy and vision. CEO Thomas Mehrling, MD, PhD, will lead the presentation and be available for one-on-one meetings, allowing for direct discussion on Helix's pipeline and milestones. This engagement is crucial for attracting investment and support, which can accelerate drug development and bring innovative treatments to market faster, benefiting the oncology sector and patients worldwide.

Helix's pipeline includes L-DOS47, a clinical-stage antibody-enzyme conjugate designed to target CEACAM6-expressing tumors, along with pre-IND candidates like LEUMUNA for post-transplant leukemia relapse and GEMCEDA, an oral gemcitabine prodrug. These developments highlight the company's focus on near-term solutions for challenging cancers, with implications for broader cancer treatment paradigms and healthcare systems. The planned NASDAQ uplisting aims to increase Helix's visibility and access to global capital markets, facilitating further research and expansion, which could drive innovation in oncology and economic growth in the biopharmaceutical industry.

Investors can access the webcast at https://investorsummitgroup.com/presentor/q3-track-1-helix-biopharma-corp/ and register for the event at https://investorsummitgroup.fillout.com/t/8CZGk3gSQbus. The outcomes of this presentation and subsequent investor interactions could influence Helix's ability to secure funding and advance its clinical trials, ultimately impacting cancer treatment advancements and market dynamics in the biotech sector.